Skip to main content
Premium Trial:

Request an Annual Quote

Link Technologies Inks Japanese Distribution Deal

NEW YORK (GenomeWeb News) – Following its first distribution deal for Asia, Link Technologies today announced another deal covering that region, this time with Japanese firm GeneDesign

Under the terms of the agreement, GeneDesign will represent Link throughout Japan. The agreement comes about a month after Link forged a distribution agreement with Zirench Technology covering China.

"By working with GeneDesign, we will be able to provide local access to our high quality products and offer our expert support services to customers throughout Japan," Link CEO John Bremner said in a statement. "This level of accessibility is something we are very keen to continue to develop within Asia and worldwide, and forms part of our ongoing strategic plans for development and growth."

Financial and other terms were not disclosed.

Link is based in Bellshill, Scotland and supplies specialty reagents for oligonucleotide synthesis and modification. GeneDesign is a contract manufacturing organization headquartered in Osaka, Japan. It also provides contract research organization services focused on oligonucleotide chemistry.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.